About Biocon
Biocon Limited develops and sells biotechnology products for the pharmaceutical sector in India and internationally. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, opthalmics, peptides, oral anti-diabetic agents, anti-inflammatory agents, hepatoprotective agents, and probiotics; and biosimilars comprising human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, filgrastim, streptokinase, and monoclonal antibodies. The company also provides branded formulations in the areas of diabetology, oncotherapeutic, nephrology, cardiology, immunotherapy, comprehensive care and bioproducts; and out-licensing services. In addition, it offers contract manufacturing services, including mammalian cell culture fermentation, microbial cell culture fermentation, and synthetic chemistry to small-to-medium sized pharmaceutical and biotech companies; undertakes clinical research activities on discovering new biomarkers; and provides integrated contract research services to support discovery and development, for small and large molecules. The company was founded in 1978 and is headquartered in Bengaluru, India.
